Molecular Partners Ag (MOLN) Return on Capital Employed (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Return on Capital Employed of 215357.42% for Q1 2026, down 21535732.0% year-on-year from N/an in Q1 2025, and down 25.82% on a QoQ basis from 171159.25% in Q4 2025.
Molecular Partners Ag (MOLN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Return on Capital Employed for 6 consecutive years, with 215357.42% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed fell 21535732.0% year-over-year to 215357.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 215357.42% (down 21535732.0% YoY) and the FY2025 annual result came in at 80.39%, down 4360.0% from the prior year.
- Return on Capital Employed declined to 215357.42% in Q1 2026 per MOLN's latest filing, from 171159.25% in the prior quarter.
- Over the last five years, Return on Capital Employed for MOLN reached as high as 0.22% in Q1 2023 and fell as low as 215357.42% in Q1 2026.
- A 5-year average of 31546.21% and a median of 0.08% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 31 bps — and 2026, when it sank 21535732 bps.
- Year by year, Return on Capital Employed stood at 0.2% in 2022, then sank by 135 bps to 0.07% in 2023, then plunged by 32 bps to 0.09% in 2024, then tumbled by 190894679 bps to 171159.25% in 2025, then declined by 26 bps to 215357.42% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 215357.42%, 171159.25%, and 149768.94% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -215,357.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -215,357.42% |
| Dec 31, 2025 | -171,159.25% |
| Sep 30, 2025 | -149,768.94% |
| Jun 30, 2025 | -0.11% |
| Mar 31, 2025 | -0.10% |
| Dec 31, 2024 | -0.09% |
| Sep 30, 2024 | -0.09% |
| Jun 30, 2024 | -0.08% |
| Mar 31, 2024 | -0.08% |
| Dec 31, 2023 | -0.07% |
| Sep 30, 2023 | 0.09% |
| Jun 30, 2023 | 0.08% |
| Mar 31, 2023 | 0.22% |
| Dec 31, 2022 | 0.20% |
| Sep 30, 2022 | 0.06% |
| Jun 30, 2022 | 0.05% |
| Mar 31, 2022 | -0.06% |
| Dec 31, 2021 | -0.11% |